No Data
Neumora Therapeutics Shares Are Trading Higher. B of A Securities Maintained a Buy Rating on the Stock.
B of A Securities Maintains Buy on Neumora Therapeutics, Lowers Price Target to $7
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA) and Idexx Laboratories (IDXX)
Trending Stocks as Wall Street Steps Into First Days of 2025 With Cautiousness
Sector Update: Health Care Stocks Higher Friday Afternoon
Neumora Therapeutics Up Over 16%, on Pace for Largest Percent Increase Since December 2023 -- Data Talk
still a super good buy now. Analysts cannot predict the future of the experiment results, so I’d say just do our own due diligence